Welcome to our dedicated page for Invitro Internat news (Ticker: IVRO), a resource for investors and traders seeking the latest updates and insights on Invitro Internat stock.
The IVRO news page on Stock Titan compiles press releases and updates from InVitro International, a company that describes itself as a pioneer developer and marketer of globally approved NON-Animal test technologies. These news items provide context on how the business connects its in vitro safety testing methods with regulatory, financial, and strategic developments.
Readers can find detailed announcements about quarterly and annual financial results, where InVitro International reports sales, net income, and commentary on profitability. Management statements in these releases often discuss how economic conditions, such as Covid-related and inflationary challenges, intersect with the company’s long-term focus on non-animal testing and its plans for growth.
News coverage also highlights regulatory and legislative changes that affect the adoption of non-animal testing. InVitro International’s releases reference actions by regulatory agencies and governments, including decisions to stop funding animal testing, accept OECD-validated non-animal test results, and restrict cosmetics that rely on animal testing. The company frames these developments as supportive of its NON-Animal test technologies.
Another recurring theme in IVRO news is corporate strategy and M&A activity. The company reports on its intent to grow both organically and through mergers and acquisitions, including a Memorandum of Understanding to merge with a European-based non-animal testing focused organization and efforts to qualify privately owned candidate laboratories. It also announces engagements with advisory firms and plans to apply for an uplisting to OTCQB.
For investors and observers interested in non-animal safety testing, animal welfare trends, and IVRO’s financial and strategic progress, this news page offers an organized view of the company’s public communications over time.
Summary not available.
Summary not available.
Summary not available.
InVitro International (OTC PINK:IVRO) announced its pursuit of strategic partnerships through ongoing Letter of Intent discussions. While outcomes remain uncertain, this move aligns with the company’s goal to advance non-animal testing. Following a robust 3rd Quarter of FY 2021, sales surged by 51% compared to the 2nd Quarter, accompanied by a cash reserve increase to $1.3 million. The company specializes in non-animal testing methods, offering technologies with global reach.
InVitro International (OTC PINK:IVRO) reported Q3 FY 2021 revenues of $310,700, a 35% increase year-over-year, and net income of $87,644. Year-to-date net income is $97.7K, up 17% from last year. Cash reserves stand at approximately $1.3M, bolstered by PPP loans. The company aims to enhance its mission of promoting non-animal testing methods, aligning with growing public sentiment against animal testing, amid recent legislative changes in multiple U.S. states.
InVitro International (OTC PINK:IVRO) reported a net income of $10,094 for the first half of fiscal 2021, a stark decline of 86% compared to $71,950 in the prior year. The company faced a net loss of $57,704 in the second quarter ending March 31, 2021. YTD revenues decreased by 32% to $406,365. Despite Covid-19's impact, IVRO is optimistic about recovery as March sales approached the combined revenues of previous months. The company's in vitro testing technology has gained acceptance in 37 countries, aligning with a global trend against animal testing.
InVitro International (IVRO) reported a net income of $67,663 for Q1 2021, reflecting a 40% increase from $48,177 in Q1 2020. This growth was attributed to a forgivable PPP loan charge, despite revenue declines due to Covid-19. The company aims to reduce animal testing through its plant-based predictive technology, recently accepted by OECD in 37 countries. New partnerships for testing and adjustments in China’s animal testing regulations signal potential growth. The company has added experienced board member Steven Pitassi to enhance fundraising efforts.